BioMedNewsBreaks

FridayJul 17, 2026 3:23 pm

BioMedNewsBreaks — MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Advances Voice-Based AI Technology for Real-Time Impairment Detection

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) is developing an AI-powered voice analysis platform designed to rapidly detect drug and alcohol impairment from short speech samples, offering a non-invasive alternative to traditional breath, saliva, urine and laboratory-based testing. Trained on more than 50 million data points and analyzing over 140 acoustic markers, the technology aims to deliver real-time impairment assessments through Edge AI kiosks, with initial field testing planned in 2026 and an initial commercial focus on South American mining operations, where large-scale workforce screening presents significant safety…

Continue Reading

ThursdayJul 16, 2026 2:56 pm

BioMedNewsBreaks — Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Poised at the Intersection of AI and Precision Medicine

Cardio Diagnostics Holdings (NASDAQ: CDIO) is leveraging artificial intelligence, epigenetics, and genetics to improve the early detection and diagnosis of coronary heart disease through its blood-based Epi+Gen CHD and PrecisionCHD tests, addressing a cardiovascular disease market projected to grow from $393 billion in annual healthcare costs in 2020 to $1.4 trillion by 2050. The company’s proprietary AI-driven Multi-Omics Engine analyzes genetic and epigenetic biomarkers to assess heart attack risk and identify coronary heart disease, including certain nonobstructive forms that conventional diagnostic methods may miss. Cardio Diagnostics has strengthened its commercialization efforts through securing finalized CMS reimbursement rates and dedicated CPT laboratory codes,…

Continue Reading

ThursdayJul 16, 2026 11:46 am

BioMedNewsBreaks — BioAdaptives, Inc. (OTC: BDPT) Details Xcellara(TM) Platform Strategy Ahead of XcellaraHeart(TM) Launch 

BioAdaptives (OTC: BDPT) outlined the scientific strategy behind its Xcellara(TM) cellular wellness platform ahead of the planned Aug. 1 commercial launch of XcellaraHeart(TM). The platform combines a stem/progenitor cell mobilization base, supported by a human randomized controlled trial showing an average 268.8% increase in circulating stem/progenitor-type cells, with tissue-specific ingredients designed to support the body's natural signaling pathways and direct those cells to targeted areas. XcellaraHeart, the platform's first commercial application, pairs the Xcellara base with Tanshinone IIA, a Danshen-derived compound studied for its role in cardiovascular SDF-1α/CXCR4 signaling. BioAdaptives said it plans to expand the platform with additional formulas targeting wellness categories including joint mobility, skin health, cognitive wellness and metabolic resilience using the same…

Continue Reading

WednesdayJul 15, 2026 2:46 pm

BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Brings AI and Robotics Together in New Platform

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a recent article that discussed the company’s launch of an AI-powered manufacturing services platform designed to help emerging biotechnology companies overcome one of the industry’s biggest challenges: accessing full GMP infrastructure. “The platform combines Oncotelic’s proprietary PDAOAI(TM) architecture with digital manufacturing technologies and intelligent robotics developed in collaboration with TechForce Robotics, the company’s strategic robotics and automation partner. The goal is not simply to apply AI to drug discovery, but to bring it into the manufacturing workflows that determine whether a therapy moves efficiently from development toward commercialization.” Already deployed at Oncotelic’s GMP-certified SAPU manufacturing facility to…

Continue Reading

WednesdayJul 15, 2026 10:43 am

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Receives European Approval for Next-Generation GelrinC Manufacturing Process

Regentis Biomaterials (NYSE American: RGNT) announced it has received approval from the European Notified Body to manufacture GelrinC(R) using its next-generation solvent-free manufacturing process, a milestone that supports the product's planned commercial launch in Europe. The company said the new process increases production yield by approximately 400%, producing five times more product from the same manufacturing volume while improving manufacturing efficiency, scalability and occupational and environmental safety. Extensive clinical testing validated consistent product quality and clinical performance. GelrinC(R), which has already received CE Mark approval in Europe, is a proprietary, cell-free hydrogel implant designed to regenerate cartilage through a minimally invasive 10-minute procedure. Regentis said commercialization will be supported…

Continue Reading

TuesdayJul 14, 2026 2:25 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development of Neuroprotective Therapy

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) was featured in a recent article that discussed its advancement of its proprietary multiple sclerosis therapy candidate, LUCID-MS, which is designed to target demyelination and protection or restoration of myelin integrity. The company reported that Phase 1 clinical studies in healthy volunteers demonstrated a favorable safety profile and that the therapy was generally well tolerated, supporting advancement into patient-focused studies. In April 2026, Quantum BioPharma submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS, paving the way…

Continue Reading

TuesdayJul 14, 2026 1:51 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Delivers Strong Fiscal Year as Healthcare Businesses Turn Cash-Flow Positive

Earth Science Tech (OTC: ETST) recently reported a transformational fiscal 2026, highlighting continued expansion of its diversified healthcare platform, strong operational execution, and a disciplined capital allocation strategy. The company said several core businesses—including DOConsultation, Villas Health, and MOC Teledoc—are now cash-flow positive, while Peaks Curative surpassed $2 million in revenue during the first week of fiscal Q4. ETST also emphasized its debt-free growth strategy, noting that healthcare expansion, infrastructure investments, and acquisitions were completed without adding debt. In addition, the company has repurchased and retired more than 6.9 million shares since fiscal Q1 2026 to reduce dilution and enhance shareholder…

Continue Reading

TuesdayJul 14, 2026 9:00 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Patent Expands Cardiac Monitoring Platform With Heart Failure and Structural Heart Disease Capabilities

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, has received a new U.S. patent covering the integration of acoustic sensing and thoracic impedance measurement into its credit card-sized, cable-free ECG device. The expanded capabilities are designed to support future applications in structural heart disease and heart failure monitoring by enabling the device to function as a digital stethoscope and assess fluid accumulation in the chest without changing its existing form factor. The patent strengthens HeartBeam's intellectual property portfolio by adding capabilities that could enable earlier detection of heart valve abnormalities and fluid congestion in heart failure…

Continue Reading

MondayJul 13, 2026 10:15 am

BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Expands TONMYA Medicare Coverage to 145 Million Lives

Tonix Pharmaceuticals (NASDAQ: TNXP) announced a major managed Medicare agreement for TONMYA(R) (cyclobenzaprine HCl sublingual tablets), adding approximately 9 million Medicare beneficiaries effective Jan. 1, 2027. Combined with previously announced commercial coverage agreements and broad Medicaid availability, the company said TONMYA will have pharmacy coverage reaching approximately 145 million covered lives, or 46% of the U.S. covered market, while discussions with additional commercial and Medicare payers continue. Following the expanded coverage and positive launch metrics, Tonix plans to add 50 sales representatives by mid-third quarter 2026, increasing its commercial sales force to approximately 150 people. The company said it is…

Continue Reading

MondayJul 13, 2026 9:30 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development

VERAXA Biotech (NASDAQ: VRXA) announced a collaboration with AI-driven bioinformatics company Ardigen S.A. to support development of its BiTAC(R) pipeline of T-cell engagers and future antibody-drug conjugates. The partnership will initially focus on developing AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA's BiTAC platform, which is designed to improve tumor targeting while reducing off-target toxicity. VERAXA said integrating artificial intelligence into its research and development strategy could enhance target selection by analyzing large preclinical and clinical datasets, including programs that demonstrated efficacy but failed because of toxicity. The company believes the collaboration will strengthen development of precision…

Continue Reading